Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.

Michael A BadruddojaMarjorie PazziAbhay SananKurt SchroederKevin KuzmaThomas NortonThomas Scully Daruka Mahadevan Michael Malek Ahmadi

Published in: Cancer chemotherapy and pharmacology (2017)

Bevacizumab plus bi-weekly temozolomide was well tolerated and may be a salvage regimen to be considered in a subset of patients with recurrent glioblastoma.

Keyphrases

phase ii study
metastatic colorectal cancer
open label
locally advanced
squamous cell carcinoma
placebo controlled
randomized controlled trial
radiation therapy
clinical trial
rectal cancer